22-23 June 2022, The Broad Institute, Cambridge, MA
PrecisionLife is presenting at the Precision Medicine Leaders Summit’s Multiomics in Precision Medicine event being held on 22-23 June at the Broad Institute in Cambridge, Massachusetts.
Our SVP Healthcare, Simon Beaulah will present ‘Addressing Unmet Medical Needs and Valuable Insights into the Biology of Complex Chronic Diseases’ on the main stage from midday on Day Two, Thursday 23 June.
The presentation is a must-see for any drug developers, precision medicine companies or healthcare organizations innovating to improve outcomes for patients with chronic diseases such as Alzheimer’s, schizophrenia, Parkinson’s, diabetes, asthma, and cardiovascular disease.
Attending Simon’s presentation, you will gain an understanding of how this new approach to precision medicine is pioneering the development of better, more personalized therapy options:
- Driving novel target discovery in areas of unmet clinical need
- Identifying new opportunities for existing drugs in novel indications
- Enabling more focused clinical trials to demonstrate efficacy and reduce time to market
In the last decade, fewer than 10% of the targets investigated in drug discovery programs have led to approved drugs. The ‘blockbuster’ discovery strategy does not work well for complex, chronic diseases, leading to expensive late-stage clinical trial failures, mainly due to inability to demonstrate clinical efficacy in patients.
Chronic diseases are especially complex, involving the interplay of multiple genetic, clinical and epidemiological factors, making finding the druggable targets underpinning these heterogenous diseases particularly difficult using existing drug discovery approaches. This leaves significant pockets of patients with unmet medical needs.
To create better, more personalized therapy options so that we can help patients to live longer, healthier lives we need to accurately determine which targets are driving disease within clinically relevant patient subgroups.
High-resolution patient stratification based on combinatorial analytics offers an accurate and scalable route to map effective targets, mechanisms, and drugs to patient subgroups across multiple new disease indications, providing a faster, cheaper and derisked route to their approval.
